Every 10-Q that Entrada Therapeutics, Inc. (TRDA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TRDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRDA filings page.
Entrada Therapeutics filed its quarterly report for the period ended June 30, 2026, reporting a Q2 2026 net loss of $42.8 million and a six‑month net loss of $82.5 million. Collaboration revenue was $0.9 million in Q2 and $1.8 million year‑to‑date, down from the prior year after earlier completion of major Vertex-related research milestones.
Research and development expenses were $35.4 million in Q2 and $68.4 million for six months, slightly below 2025, while general and administrative expenses were $10.5 million in Q2. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $223.0 million; the company believes this will fund operations into the third quarter of 2027.
Clinically, Entrada highlighted Cohort 1 data from its ELEVATE‑44‑201 trial of ENTR‑601‑44 in Duchenne muscular dystrophy, showing a mean dystrophin increase to 6.36% (up 2.36 percentage points from baseline) and statistically significant improvements in Time to Rise and Time to Rise velocity versus placebo at a 6 mg/kg dose. Multiple additional DMD and ocular programs, and the VX‑670 DM1 collaboration with Vertex, continue to advance with several data readouts expected between late 2026 and early 2027.
Entrada Therapeutics reported a larger loss for the quarter ended March 31, 2026 as it invested heavily in its genetic medicines pipeline. Collaboration revenue fell to $0.9 million from $20.6 million a year earlier, mainly because work under its Vertex partnership wound down.
Research and development expenses were $33.1 million and general and administrative costs were $10.1 million, leading to a net loss of $39.7 million, or $0.95 per share, versus a $17.3 million loss, or $0.42 per share, in the prior-year period.
Cash, cash equivalents and marketable securities totaled $254.9 million, which the company believes can fund operations into the third quarter of 2027. Entrada is advancing multiple Duchenne muscular dystrophy programs, including ENTR-601-44 and ENTR-601-45, and its partnered DM1 candidate VX-670 with Vertex, with several data readouts expected in 2026.
Entrada Therapeutics (TRDA) filed its Q3 2025 10‑Q, reporting a sharp year-over-year step-down in collaboration revenue and a return to losses as prior-period milestone revenue tapered. Collaboration revenue was $1.6 million for the quarter versus $19.6 million a year ago, and $24.1 million for the nine months versus $173.4 million in 2024. Research and development expenses rose to $38.4 million in Q3 (from $31.3 million), reflecting advancing DMD programs; general and administrative expenses were $10.3 million (from $10.0 million).
The company posted a net loss of $44.1 million for Q3 (vs. $14.0 million loss) and a net loss of $104.6 million year‑to‑date (vs. $64.5 million income), with Q3 EPS of $(1.06). Cash, cash equivalents and marketable securities totaled $326.8 million as of September 30, 2025, which management states is sufficient to fund operations into the third quarter of 2027. Operating cash use was $96.3 million year‑to‑date. Deferred revenue declined to $0.5 million, consistent with revenue recognition on the Vertex collaboration.
Pipeline updates include ongoing Phase 1/2 studies for ENTR‑601‑44 and ENTR‑601‑45 in DMD, UK filing for ENTR‑601‑50, and a planned ENTR‑601‑51 filing in 2026. A 20% workforce reduction in April 2025 resulted in a $1.9 million charge. Shares outstanding were 38,219,232 as of October 31, 2025.
Entrada Therapeutics, Inc. (Form 10-Q) — quarter ended June 30, 2025. The company reported $72.5M cash and cash equivalents and $281.5M marketable securities (total $354.0M) and total assets of $448.8M as of June 30, 2025. Total liabilities were $69.3M and accumulated deficit was $189.8M. Shares outstanding: 38,033,970 as of June 30, 2025 (38,037,079 as of July 31, 2025).
Operational and financial results: collaboration revenue was $1.95M for Q2 2025 and $22.51M for the six months ended June 30, 2025 (versus $94.69M and $153.81M in the comparable 2024 periods). R&D expense was $37.88M in Q2 2025 and $69.95M for six months; G&A expense was $10.92M and $21.20M, respectively. Net loss: $43.10M for the quarter and $60.45M for six months (basic net loss per share Q2: $1.04; six months: $1.47).
Corporate developments: first patient dosed in ELEVATE-44-201 and ELEVATE-45-201 initiated; company expects to file for ENTR-601-50 in Q4 2025. Vertex collaboration revenue recognition included a cumulative catch-up adjustment of $12.3M during H1 2025 and the remaining transaction price allocated to unsatisfied obligations was $0.9M at June 30, 2025. The company implemented a ~20% workforce reduction in April 2025 with a related charge of $1.9M. Management states liquidity is sufficient to fund operations into the second quarter of 2027.